Extensive preclinical studies established the oncogenic roles of FGFR2b, CLDN18.2, and VEGFR2 in gastric cancer, providing a strong rationale for developing targeted monoclonal antibodies—bemarituzumab, zolbetuximab, and ramucirumab. The gene discussed is KDR; the disease is gastric cancer.